Specenier P - Search Results

1

Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor.

Boeckx C, Blockx L, de Beeck KO, Limame R, Camp GV, Peeters M, Vermorken JB, Specenier P, Wouters A, Baay M, Lardon F. Boeckx C, et al. Among authors: specenier p. Am J Cancer Res. 2015 May 15;5(6):1921-38. eCollection 2015. Am J Cancer Res. 2015. PMID: 26269754 Free PMC article.

2

The role of taxanes and targeted therapies in locally advanced head and neck cancer.

Specenier P, Vermorken JB. Specenier P, et al. Curr Opin Oncol. 2007 May;19(3):195-201. doi: 10.1097/CCO.0b013e3280f00fe7. Curr Opin Oncol. 2007. PMID: 17414636 Review.

3

Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy.

Specenier P, Koppen C, Vermorken JB. Specenier P, et al. Ann Oncol. 2007 May;18(5):961-2. doi: 10.1093/annonc/mdm116. Epub 2007 Apr 17. Ann Oncol. 2007. PMID: 17442661 Free article. No abstract available.

4

Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?

Specenier PM, Vermorken JB. Specenier PM, et al. Cancer Lett. 2007 Oct 28;256(2):166-77. doi: 10.1016/j.canlet.2007.06.015. Epub 2007 Jul 27. Cancer Lett. 2007. PMID: 17673364 Review.

5

Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data.

Specenier PM, Van den Weyngaert D, Van Laer C, Weyler J, Van den Brande J, Huizing MT, Dyck J, Schrijvers D, Vermorken JB. Specenier PM, et al. Ann Oncol. 2007 Nov;18(11):1856-60. doi: 10.1093/annonc/mdm346. Epub 2007 Sep 6. Ann Oncol. 2007. PMID: 17823386 Free article. Clinical Trial.

6

Recurrent head and neck cancer: current treatment and future prospects.

Specenier PM, Vermorken JB. Specenier PM, et al. Expert Rev Anticancer Ther. 2008 Mar;8(3):375-91. doi: 10.1586/14737140.8.3.375. Expert Rev Anticancer Ther. 2008. PMID: 18366286 Review.

7

Current concepts for the management of head and neck cancer: chemotherapy.

Specenier PM, Vermorken JB. Specenier PM, et al. Oral Oncol. 2009 Apr-May;45(4-5):409-15. doi: 10.1016/j.oraloncology.2008.05.014. Epub 2008 Aug 19. Oral Oncol. 2009. PMID: 18715812 Review.

8

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.

Specenier PM, Ciuleanu T, Latz JE, Musib LC, Darstein CL, Vermorken JB. Specenier PM, et al. Cancer Chemother Pharmacol. 2009 Jul;64(2):233-41. doi: 10.1007/s00280-008-0853-0. Epub 2008 Nov 15. Cancer Chemother Pharmacol. 2009. PMID: 19011858 Clinical Trial.

9

A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.

Specenier PM, Weyler J, Van Laer C, Van den Weyngaert D, Van den Brande J, Huizing MT, Altintas S, Vermorken JB. Specenier PM, et al. BMC Cancer. 2009 Aug 6;9:273. doi: 10.1186/1471-2407-9-273. BMC Cancer. 2009. PMID: 19660134 Free PMC article.

10

Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck.

Specenier PM, Van Den Brande J, Schrijvers D, Huizing MT, Altintas S, Dyck J, Van Den Weyngaert D, Van Laer C, Vermorken JB. Specenier PM, et al. Anticancer Res. 2009 Dec;29(12):5137-42. Anticancer Res. 2009. PMID: 20044628 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

87 results

Search Page

Filters